FDG-PET metabolic tumor volume in advanced melanoma treated with ipilimumab and nivolumab (ipi/nivo).

被引：0
|
作者：
Iravani, Amir
Wallace, Roslyn
Lo, Serigne
Galligan, Anna
Weppler, Alison
Au-Yeung, George
Kee, Damien
Lau, Peter Kar Han
Brady, Benjamin M.
Lee, Belinda
McArthur, Grant A.
Sandhu, Shahneen Kaur
Hicks, Rodney J.
机构：
[1] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[2] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10041
引用
收藏
页数：2
相关论文
共 50 条
  • [21] ECONOMIC EVALUATION OF NIVOLUMAB (NIVO) PLUS IPILIMUMAB (IPI) COMBINATION AS FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED MELANOMA IN CANADA
    Quon, P.
    Xiao, Y.
    Sorensen, S.
    Schultz, M.
    Monfared, Tahami A. A.
    VALUE IN HEALTH, 2017, 20 (09) : A441 - A442
  • [22] Assessing the value of nivolumab (NIVO) versus placebo (PBO) and ipilimumab (IPI) as adjuvant therapy for resected melanoma
    Freeman, Morganna Louise
    Shoushtari, Alexander Noor
    Betts, Keith A.
    Gupte-Singh, Komal
    Du, Ella X.
    Ritchings, Corey
    Rao, Sumati
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [23] Early Reassessment of Total Metabolic Tumor Volume on FDG-PET/CT in Advanced Melanoma Patients Treated with Pembrolizumab Predicts Long-Term Outcome
    Vermeulen, Sim
    Awada, Gil
    Keyaerts, Marleen
    Neyns, Bart
    Everaert, Hendrik
    CURRENT ONCOLOGY, 2021, 28 (03) : 1630 - 1640
  • [24] Longitudinal analysis of circulating immune cell subsets in melanoma patients (pts) treated with neo-adjuvant ipilimumab (ipi) & nivolumab (nivo)
    Simpson, R. C.
    Batten, M.
    Shanahan, E. R.
    Da Silva, I. Pires
    Versluis, J. M.
    Reijers, I. L. M.
    Menzies, A. M.
    Saw, R. P. M.
    Gonzalez, M.
    Shannon, K. F.
    Spillane, A. J.
    Blank, C. U.
    Scolyer, R. A.
    Long, G. V.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1303 - S1303
  • [25] Combining ipilimumab (ipi) and nivolumab (nivo) in advanced melanoma following progression on a PD-1 inhibitor (SWOG S1616)
    Vanderwalde, Ari M.
    Latkovic-Taber, Michaella
    Hu-Lieskovan, Siwen
    Grossmann, Kenneth F.
    Sosman, Jeffrey Alan
    Campos, Danae
    Wu, Michael
    Ribas, Antoni
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] Phase II study of nivolumab (nivo) and ipilimumab (ipi) for advanced bladder cancer with variant histologies (BCVH)
    McGregor, B. A.
    Campbell, M. T.
    Huang, J.
    Xie, W.
    Bilen, M. A.
    Mortazavi, A.
    Ravi, P.
    Shah, A.
    Einstein, D.
    Sonpavde, G. P.
    McKay, R. R.
    Siefker-Radtke, A. O.
    Bellmunt, J.
    Choueiri, T. K.
    ANNALS OF ONCOLOGY, 2023, 34 : S1205 - S1206
  • [27] The safety and early efficacy of high-dose ipilimumab (IPI) and the combination nivolumab plus ipilimumab (NIVO plus IPI) in patients (pts) with uveal melanoma (UM).
    Patel, Sapna Pradyuman
    Glitza, Isabella Claudia
    Diab, Adi
    Amaria, Rodabe Navroze
    Davies, Michael A.
    Hwu, Patrick
    Tawbi, Hussein Abdul-Hassan
    Hwu, Wen-Jen
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [28] Association of distinct baseline tissue biomarkers with response to nivolumab (NIVO) and ipilimumab (IPI) in melanoma: CheckMate 064.
    Rodig, Scott
    Gusenleitner, Daniel
    Jackson, Donald
    Gjini, Evisa
    Giobbie-Hurder, Anita
    Jin, Chelsea
    Chang, Han
    Lovitch, Scott
    Horak, Christine
    Weber, Jeffrey S.
    Shipp, Margaret Ann
    Hodi, F. Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [29] FDG-PET in the assessment of metabolic response in patients with NSCLC treated with nivolumab: Preliminary results
    Goldfarb, L.
    Duchemann, B.
    Chouahnia, A.
    Pop, G.
    Gomez, L.
    Zelek, L.
    Soussan, M.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 : S673 - S673
  • [30] FDG-PET/CT response and prediction of pathological response to neoadjuvant nivolumab and ipilimumab for clinical stage III melanoma
    De Barros E Silva, Milton Jose
    Tavares, Monique Celeste
    Lima, Joao Paulo S. N.
    Buzaid, Antonio C.
    Garcia, Daniel
    De Camargo, Veridiana Pires
    Molina, Andre
    Bertolli, Eduardo
    Lobo, Matheus
    Jonathan Van Akkooi, Alexander Christopher
    Pinto, Clovis
    De Paula, Rafaela Brito
    Lima, Eduardo
    Rinck, Jose Augusto
    Duprat, Joao
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345